Imugene Limited (ASX:IMU)

Imugene Statistics

Total Valuation

Imugene has a market cap or net worth of AUD 115.37 million. The enterprise value is 104.09 million.

Market Cap	115.37M
Enterprise Value	104.09M

Important Dates

The next estimated earnings date is Thursday, November 27, 2025.

Earnings Date	Nov 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Imugene has 295.83 million shares outstanding. The number of shares has increased by 4.90% in one year.

Current Share Class	295.83M
Shares Outstanding	295.83M
Shares Change (YoY)	+4.90%
Shares Change (QoQ)	+0.76%
Owned by Insiders (%)	9.39%
Owned by Institutions (%)	4.94%
Float	259.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.24
PB Ratio	2.56
P/TBV Ratio	8.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.51
EV / Sales	23.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.25

Financial Position

The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.24.

Current Ratio	1.88
Quick Ratio	1.44
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-0.13
Interest Coverage	-431.20

Financial Efficiency

Return on equity (ROE) is -84.54% and return on invested capital (ROIC) is -49.98%.

Return on Equity (ROE)	-84.54%
Return on Assets (ROA)	-37.27%
Return on Invested Capital (ROIC)	-49.98%
Return on Capital Employed (ROCE)	-114.04%
Revenue Per Employee	879,363
Profits Per Employee	-13.80M
Employee Count	5
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.65% in the last 52 weeks. The beta is 3.37, so Imugene's price volatility has been higher than the market average.

Beta (5Y)	3.37
52-Week Price Change	-76.65%
50-Day Moving Average	0.33
200-Day Moving Average	0.67
Relative Strength Index (RSI)	54.82
Average Volume (20 Days)	3,352,087

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Imugene had revenue of AUD 4.40 million and -69.02 million in losses. Loss per share was -0.32.

Revenue	4.40M
Gross Profit	4.40M
Operating Income	-70.06M
Pretax Income	-69.02M
Net Income	-69.02M
EBITDA	-67.42M
EBIT	-70.06M
Loss Per Share	-0.32

Balance Sheet

The company has 21.94 million in cash and 10.65 million in debt, giving a net cash position of 11.28 million or 0.04 per share.

Cash & Cash Equivalents	21.94M
Total Debt	10.65M
Net Cash	11.28M
Net Cash Per Share	0.04
Equity (Book Value)	45.03M
Book Value Per Share	0.21
Working Capital	19.59M

Cash Flow

In the last 12 months, operating cash flow was -75.57 million and capital expenditures -7.55 million, giving a free cash flow of -83.12 million.

Operating Cash Flow	-75.57M
Capital Expenditures	-7.55M
Free Cash Flow	-83.12M
FCF Per Share	-0.28

Margins

Gross Margin	100.00%
Operating Margin	-1,593.52%
Pretax Margin	-1,569.81%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Imugene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.90%
Shareholder Yield	-4.90%
Earnings Yield	-59.82%
FCF Yield	-72.04%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 2, 2025. It was a reverse split with a ratio of 0.0294117647.

Last Split Date	Jul 2, 2025
Split Type	Reverse
Split Ratio	0.0294117647

Scores

Imugene has an Altman Z-Score of -3.85 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.85
Piotroski F-Score	1